Guggenheim analyst Yatin Suneja raised the firm’s price target on Biogen (BIIB) to $246 from $185 and keeps a Buy rating on the shares. The firm, which adjusted its model following Q4 earnings, sees upcoming milestones that “re-anchor the investment narrative around a pipeline with multiple shots on goal,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen, Eisai say BLA for Leqembi accepted for Priority Review by NMPA of China
- Biogen price target raised to $201 from $191 at Bernstein
- Biogen price target raised to $228 from $194 at H.C. Wainwright
- Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating
- Biogen price target raised to $200 from $190 at Wells Fargo